Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 31, 2009

View Archived Issues

Freie Universitaet Berlin claims novel pepstatin A derivatives

CKD Pharmaceuticals describes discovery of PDE5 inhibitor CKD-533

Activity of nab-rapamycin against breast cancer xenografts enhanced by other agents

Synergistic growth inhibition seen with BEZ-235 and dual EGFR and HER-2/neu inhibitor

Novel Raf kinase inhibitors presented by Wyeth as oncolytics

Esteve discloses 5-HT6 receptor ligands for the treatment of eating disorders

Novel HDAC inhibitors being developed by EnVivo Pharmaceuticals and MethylGene

Pim kinase inhibitors claimed by Novartis for the treatment of cancer

Novel Raf kinase inhibitors described by Novartis for the treatment of cancer

Takeda discovers a novel series of AMPA glutamate receptor agonists

Phase I results suggest ARRY-380 is well tolerated, active in breast cancer patients

Novo Nordisk provides update on timeline for formal FDA feedback on liraglutide

Santarus submits IND for phase III rifamycin SV MMX trial

FDA accepts NDA filing for Valeant's retigabine

Pfizer discontinues phase III figitumumab trial in non-small cell lung cancer

FDA issues complete response letter for ceftobiprole

MedImmune voluntarily recalls specific lots of 2009 H1N1 nasal spray vaccine

FDA review of Vytorin deems cancer risk "unlikely"

FDA responds to Vion's SPA request regarding Onrigin

Biotec sells Immunocorp subsidiaries in order to focus on biopharmaceuticals

Meda expands collaboration for Axorid

Clinical study of NPC-1C begins for pancreatic and colorectal cancer

BGC-20-0134 moves into phase II investigation for relapsing remitting MS

LEO-29102 enters phase II study for atopic dermatitis

Merck identifies novel macrocyclic hepatitis C NS3/4A protease inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.